Changes to prescribing antiviral and antibody treatments for COVID-19

Nirmatrelvir plus ritonavir is recommended as an option for treating COVID-19 in adults, only if they:

• do not need supplemental oxygen for COVID-19
• they are an adult and at an increased risk for progression to severe COVID-19, as defined in box 1 risk factors for progression to severe COVID‑19 in adults in section 5 of nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19

Nirmatrelvir plus ritonavir is not licensed or recommended as an option for treating COVID-19 in anyone under 18 years of age.

Referral for intravenous administration of sotrovimab is recommended as an option for treating COVID-19 in adults and young people aged 12 and over weighing at least 40 kg, only if:

• they do not need supplemental oxygen for COVID-19
• nirmatrelvir plus ritonavir is contraindicated or unsuitable
• they are an adult and at an increased risk for progression to severe COVID-19, as defined in box 1 risk factors for progression to severe COVID‑19 in adults in section 5 of nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
• they are a young person aged 12 to 17 years at an increased risk for progression to severe COVID-19, as defined in box 2 risk factors for progression to severe COVID‑19 in young people aged 12 to 17 years in section 5 of nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19

Molnupiravir is recommended as an option for treating mild to moderate COVID-19 in adults, only if:

• both nirmatrelvir plus ritonavir and sotrovimab are contraindicated or unsuitable
• they at an increased risk for progression to severe COVID-19, as defined in box 1 risk factors for progression to severe COVID‑19 in adults in section 5 of nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19.

Molnupiravir is not licensed or recommended as an option for treating COVID 19 in anyone under 18 years of age.